Pharma BD Deal Intelligence

Regeneron Pharmaceuticals, Inc. / 23andMe Holding Co.

2025 · Asset Purchase · $256M · Terminated

Regeneron was named successful bidder in 23andMe's Chapter 11 bankruptcy auction and entered an asset purchase agreement to acquire substantially all of 23andMe's assets, including the Personal Genome Service, Total Health and Research Services business lines and the associated Biobank, for $256 million in cash, excluding the Lemonaid Health telehealth subsidiary. Regeneron committed to comply with 23andMe's consumer privacy policies. The agreement did not close: the bankruptcy court reopened bidding, Regeneron declined to raise its offer, and TTAM Research Institute completed the acquisition of the assets in July 2025.

Key facts

• Announced May 19, 2025
• Deal value $256M
• Deal type Asset Purchase
• Therapeutic area Other

Related deals

• Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc. (2019)
• Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. (2026)
• Regeneron Pharmaceuticals, Inc. / Sanofi S.A. (Libtayo global rights) (2022)
• Regeneron Pharmaceuticals, Inc. / Parabilis Medicines, Inc. (2026)
• Regeneron Pharmaceuticals, Inc. / Telix Pharmaceuticals Limited (2026)
• Regeneron Pharmaceuticals, Inc. / Tessera Therapeutics, Inc. (2025)

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Regeneron Pharmaceuticals, Inc. deals  ·  Other deals